ClinicalTrials.gg
TerminatedNCT01601340Updated Mar 18, 2015

Effects of HQK-1001 in Patients With Sickle Cell Disease

A Phase 2 interventional study of HQK-1001 and Placebo in Sickle Cell Disease, Sickle Cell Anemia and Sickle Cell Disorders, sponsored by HemaQuest Pharmaceuticals Inc.. Terminated at 18 sites in 5 countries. Open to participants aged 12 Years to 60 Years. Per ClinicalTrials.gov, last updated 2015-03-18.

Sponsored by HemaQuest Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
12 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
134th of 559
77 · median 31
Started
2012
with 35 others
Phase 2
161 of 733
23 open now
Registered
203rd of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 134th largest by enrollment of the 559 interventional ones that give a count, is one of 36 that started in 2012, is one of 161 in phase 2, and was the 203rd registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of HQK-1001 on Hb F in subjects with sickle cell disease.

03

Conditions studied

  • Sickle Cell Disease
  • Sickle Cell Anemia
  • Sickle Cell Disorders
  • Hemoglobin S Disease
  • Sickling Disorder Due to Hemoglobin S

Browse trials for

04

Who can participate

Ages eligible
12 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between 12 and 60 years of age
  • Diagnosis of SCD, type SS or Hb S-B0 Thalassemia
  • At least 1 episode of SCD pain crisis, acute chest syndrome, other acute SCD complications, or leg ulcers in the 12 months prior to screening
  • Not being treated with Hydroxyurea (HU); if HU treatment has been previously administered and then discontinued, at least 3 months must have elapsed since last dose of HU
  • If subject has been transfused in the 3 months prior to screening, then Hb A level \< 20% at screening
  • Baseline Hb F level obtained within 14 days prior to randomization
  • Able to swallow tablets
  • Able and willing to give and/or assent
  • If subject is a woman of (WCBP), she must have a negative serum pregnancy test within 14 days of first dose of HQK-1001 and a negative urine pregnancy test prior to dosing on Day 1
  • If a subject is a WCBP, she must agree to use an effective form of starting at screening and for one month after HQK-1001 discontinuation
  • Sexually active male subjects who have not had a vasectomy must agree to use latex condoms with WCBP partners or ensure that their partner(s) use an effective form of contraception starting at screening and for one month after HQK-1001 discontinuation.

Exclusion criteria

Exclusion Criteria:

  • Assigned to a regular transfusion program
  • Use of erythropoiesis stimulating agents within 90 days prior to screening
  • An SCD pain crisis or SCD-related acute complication within 3 weeks prior to randomization
  • More than 5 SCD pain crisis or SCD-related acute complications within 12 months prior to screening
  • Pulmonary hypertension requiring therapy
  • or AST > 3x
  • Serum creatinine > 1.5x ULN
  • Serum amylase levels > 1.5x ULN
  • Serum lipase level > 1.5x ULN
  • A serious, concurrent illness that would limit ability to complete or comply with the study requirements
  • An acute illness (e.g., febrile, GI, respiratory) within 72 hours prior to screening
  • History of syncope, dysrhythmias or resuscitation from sudden death due to SCD-related complication
  • Symptomatic peptic ulcer, hiatus hernia, or gastroesophageal reflux disease (GERD)
  • History of pancreatitis
  • Chronic opiate use, which, in the view of the investigator, could confound evaluation of an drug
  • Current abuse of alcohol or drugs
  • Use of another investigational agent within 4 weeks or 5 half-lives, whichever is longer, prior to screening
  • Currently pregnant or breast feeding a child
  • Known infection with -1
  • Infection with or , such that subjects are currently on anti-viral therapy or will be placed on therapy
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Active comparator
    HQK-1001

    Drug: HQK-1001

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in % fetal hemoglobin

    Time frame: Day 1 through Week 48

Secondary outcomes

  1. Incidence and number of SCD pain crises and SCD-related complications

    Time frame: Day 1 through Week 52

  2. Subject reported daily pain scale scores and analgesic use

    Time frame: 7 consecutive days following clinic visits at Day 1, and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

  3. Change in FACIT Fatigue Scale results

    Time frame: Day 1 and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

  4. Safety measured by the frequency and severity of adverse events, and changes from baseline in vital signs, electrocardiogram (ECG) monitoring, and laboratory assessments

    Time frame: Day 1 through Week 52

  5. HQK-1001 pharmacokinetic parameters

    A subset of subjects (7) will undergo sampling for detailed analysis of pharmacokinetic parameters (AUC, Cmax) with samples taken pre-dose, and 1, 2, 4, 8, and 10 hours after the morning dose at Week 4.

    Time frame: 1 hour prior to, and 2 hours following morning dose on Weeks 12, 24 and 48

07

Study locations

18 sites
  • University of South Alabama
    Mobile, Alabama 36617-2238, United States
  • Children's Hospital and Research Center - Oakland
    Oakland, California 94609, United States
  • Children's National Hospital
    Washington, District of Columbia 20010, United States
  • Howard University Hospital
    Washington, District of Columbia 20060, United States
  • Georgia Health Sciences University
    Augusta, Georgia 30912, United States
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • The Children's Hospital at Montefiore Medical Center
    Bronx, New York 10467, United States
  • New York Methodist Hospital
    Brooklyn, New York 11215, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Virginia Commonwealth Univeristy - Center on Health Disparities
    Richmond, Virginia 23298, United States
  • University Health Network Toronto General Hospital
    Toronto, Ontario M5G2C4, Canada
  • Abu El Reesh Pediatric University Hospital
    Cairo, Egypt
  • Ain Sham University Hospital
    Cairo, Egypt
  • University of the West Indies
    Mona, Kingston 7, Jamaica
  • American University of Beirut Medical Center
    Beirut, Lebanon
  • Chronic Care Center
    Beirut, Lebanon
  • Rafik Hariri University Hospital
    Beirut, Lebanon
08

References and documents

Publications

  • Reid ME, El Beshlawy A, Inati A, Kutlar A, Abboud MR, Haynes J Jr, Ward R, Sharon B, Taher AT, Smith W, Manwani D, Ghalie RG. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2014 Jul;89(7):709-13. doi: 10.1002/ajh.23725. Epub 2014 Apr 15. PubMed 24677033 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Nov 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2012
First posted
May 18, 2012
Start
Jul 2012
Primary completionActual
Nov 2013
CompletionActual
Dec 2013
Last update
Mar 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01601340
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
May 18, 2012
Start date
Jul 2012
Primary completion
Nov 2013
Completion
Dec 2013
Last update
Mar 18, 2015

Study contacts

Richard Ghalie, MD, MBA
study director · HemaQuest Pharmaceuticals Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimebutic acid

Start the discussion